{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-103598","form_type":"8-K","ticker":"IMA","cik":"0001835579","company_name":"ImageneBio, Inc.","filed_at":"2022-04-13T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.713916+00:00","generated_at":"2026-06-26T07:43:28.315477+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Ikena Oncology appoints Jotin Marango as CFO and Head of Corporate Development","bullets":["Dr. Marango will assume CFO role effective April 25, 2022, succeeding interim CFO Mark Manfredi.","Base salary of $425,000; annual bonus target of 40% of base salary.","Granted option to purchase 397,199 shares, vesting 25% on one-year anniversary and rest over 36 months.","Dr. Marango previously served as SVP, CFO and CBO at Aptose Biosciences.","Severance benefits include lump-sum payments and accelerated vesting upon qualifying termination."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-103598","json":"https://secwatch.observer/filing/0001193125-22-103598.json","markdown":"https://secwatch.observer/filing/0001193125-22-103598.md","text":"https://secwatch.observer/filing/0001193125-22-103598.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835579/000119312522103598/0001193125-22-103598-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835579/000119312522103598/d323540d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T07:43:28.315477+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0bb737f752","claim":"Jotin Marango was appointed as Chief Financial Officer, Head of Corporate Development at ImageneBio, Inc..","evidence_excerpt":"appoint Jotin Marango, M.D., Ph.D. as Chief Financial Officer, Head of Corporate Development, effective April 25, 2022","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1835579/000119312522103598/0001193125-22-103598-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer, Head of Corporate Development"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}